Other Vaccines - New Zealand

New Zealand

Highlights

In New Zealand, the revenue in the Other Vaccines market is projected to reach US$64.71m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 10.43%, resulting in a market volume of US$106.30m by 2029.
When compared globally, United States is anticipated to generate the highest revenue of US$24.73bn in 2024.
New Zealand is experiencing a growing demand for other vaccines as the government prioritizes public health and proactive disease prevention measures.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in New Zealand has been experiencing steady growth in recent years.

Customer preferences: New Zealand has a well-established and efficient healthcare system, which has contributed to the high demand for vaccines in the country. The government has a strong focus on preventative healthcare, and vaccines are an important part of this strategy. Additionally, there is a high level of awareness among the population about the importance of vaccines, which has contributed to the growth of the Other Vaccines market.

Trends in the market: The Other Vaccines market in New Zealand has been growing steadily due to the increasing demand for vaccines. There has been a growing trend towards the use of combination vaccines, which offer protection against multiple diseases in a single injection. This has been driven by the convenience and cost-effectiveness of combination vaccines, as well as the increased focus on reducing the number of injections required for vaccination.

Local special circumstances: New Zealand has a relatively small population, which has led to some challenges in the distribution of vaccines. However, the government has implemented a number of initiatives to address these issues, including the development of a national immunisation schedule and the establishment of a nationwide vaccine registry. These initiatives have helped to ensure that vaccines are widely available and accessible to the population.

Underlying macroeconomic factors: New Zealand has a stable and growing economy, which has contributed to the growth of the Other Vaccines market. The government has also invested heavily in healthcare infrastructure, which has helped to support the growth of the market. Additionally, the country has a strong regulatory framework for vaccines, which has helped to ensure the safety and efficacy of vaccines in the market. Overall, the Other Vaccines market in New Zealand is expected to continue growing in the coming years, driven by the increasing demand for vaccines and the government's focus on preventative healthcare.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.